J Roberts

Classical hematologist; hemostasis/thrombosis, hemophilia, VWD, rare bleeding disorders specialist; severe hemophilia A blood brother🩸, opinions my own

[J Roberts @JonRob08]

Happy to share a recent publication to kick off bleeding disorders awareness month!

https://t.co/uh69rGLDbY

[VJHemOnc @VJHemOnc]

In a recent interview, @JonRob08 of @BloodExpertsIL discusses the findings of a study evaluating joint health status & bleeding phenotype in patients with severe & non-severe #hemophilia A or B using musculoskeletal ultrasound and other clinical tools.🩸

Watch here: 👉 https://t.co/OaF7Y4Udz7

#Hematology #ASH25

[J Roberts @JonRob08]

Interesting news and was really only a matter of time. Companies should listen to patients, and each individual weigh risks/benefits of all evolving hemophilia therapies. Sometimes patience is the wise approach. #hemophilia #genetherapy

https://t.co/9IaXxlaOyJ

[J Roberts @JonRob08]

@Brianhemophilia @WHO @wfhemophilia Strong work!!! Patients around the world will benefit from this life-saving endeavor! ❤️🙌🏽 🩸

[J Roberts @JonRob08]

@BloodExpertsIL @nbd_foundation @isth @ASH_hematology @wfhemophilia @HTRStoday @THSNA_Societies @VwdConnect @UICOMPeoria @hemophiliafed

[J Roberts @JonRob08]

Happy to share our study of recombinant VWF real-world treatment patterns and outcomes at 11 centers in the U.S. We demonstrate that routine rVWF prophylaxis reduced bleed rate and healthcare resource utilization compared to prior VWD treatments. #VWD #VWF https://t.co/vGHiJVMBQg

[J Roberts @JonRob08]

@BloodExpertsIL @nbd_foundation @isth @ASH_hematology @wfhemophilia @HTRStoday @THSNA_Societies @VwdConnect

[J Roberts @JonRob08]

@BloodExpertsIL @UICOMPeoria @VersitiResearch @Versiti @nbd_foundation @BloodAdvances @ASH_hematology

[J Roberts @JonRob08]

Proud to work with esteemed colleagues to improve future research priorities. The patient voice, through lived experience experts, must be incorporated into cutting-edge research programs from start to finish. https://t.co/gMQUL70k0C

[J Roberts @JonRob08]

@BloodExpertsIL @UICOMPeoria @VersitiResearch @Versiti @nbd_foundation

[J Roberts @JonRob08]

@docrishabhsingh has a bright future and will be a phenomenal classical hematologist 👊🏽🙏🏽 congrats 🙌🏽 👏🏽

[Rishabh Singh, MD 🩸 @docrishabhsingh]

Honored to receive the Mary Draeger Schultz scholarship 2024 @OSFHealthCare!

Grateful for the opportunity to promote #QI and #PatientSafety in healthcare, and for the incredible support from @UICOMPeoria @UicompP

[Rishabh Singh, MD 🩸 @docrishabhsingh]

Honored to receive the Mary Draeger Schultz scholarship 2024 @OSFHealthCare!

Grateful for the opportunity to promote #QI and #PatientSafety in healthcare, and for the incredible support from @UICOMPeoria @UicompP

[Mark Skinner @MSkinnerDC]

Contrasting Approaches in the Implementation of GRADE Methodology in Guidelines for Haemophilia and VWD. https://t.co/x17lE2TNNf This article developed by a global team of 48 experts and international organizations rigorously examines a number of GRADE methodology adaptations.

[Rishabh Singh, MD 🩸 @docrishabhsingh]

Come say Hi! 🍷

Poster number: 5014

https://t.co/yqnozLiATb

[Brian O Mahony @Brianhemophilia]

A critique of the ISTH Haemophilia Guidelines was published in #Haemophilia Journal today with 49 eminent authors representing a global mixture of expertise, all united in their serious concerns about these guidelines which were already outdated on publication 1/3

[Ben Samelson-Jones, MD, PhD @DrSamelsonJones]

Here is our just published review in #Blood focusing on how new biological insights into #FVIII
are setting the stage for new #hemophilia therapies.

#hemesky #medsky

https://t.co/ZpAWXNbBEW

[J Roberts @JonRob08]

@AaronGoodman33 Staying

[J Roberts @JonRob08]

@nbd_foundation @BloodExpertsIL

[National Bleeding Disorders Foundation @nbd_foundation]

With 70% of bleeding events linked to identified or suspected causes, this study highlights the pressing need for better strategies, including long-term VWD factor (VWF) prophylaxis, to reduce hospitalizations and improve quality of life. Read More: https://t.co/IJoEN9Npnu

[Brian O Mahony @Brianhemophilia]

Centessa have discontinued development of their rebalancing agent, Serpin PC despite encouraging Phase 2 PREScent clinical trial results Decision due to competition from marstacimab and possibly concizumab. This leaves these 2 plus Fitusiran in trials or licenced @ProfMakris